Ensacove-Ensartinib
Ensacove is an oral kinase inhibitor for adults with ALK-positive, locally advanced or metastatic non-small cell lung cancer who haven’t previously received ALK-targeted therapy. It blocks ALK-driven signaling to help control tumor growth and delay disease progression.
Tryngolza-Olezarsen
Tryngolza is a subcutaneous injection for adults with familial chylomicronemia syndrome. It reduces APOC-III protein levels to lower dangerously high triglycerides and prevent pancreatitis.
Orlynvah-Sulopenem Etzadroxil And Probenecid
Orlynvah is an oral tablet for adult women with uncomplicated urinary tract infections caused by E. coli, K. pneumoniae, or P. mirabilis, especially for those with limited or no alternative oral antibiotic options. It combines sulopenem (an antibiotic) with probenecid, which helps increase sulopenem levels, delivering strong antibacterial activity comparable or superior to ciprofloxacin and […]
Revuforj-Revumenib Citrate
Revuforj is a drug used to treat relapsed or refractory acute leukemia. The treatment of acute leukemia is done with a lysine methyltransferase 2A gene translocation (KMT2A) in adults. This drug is also indicated for children 1 year and older whose disease has come back or has not improved after previous treatments.
Attruby-Acoramidis
Attruby is an oral tablet for adults with transthyretin amyloid cardiomyopathy (wild-type or hereditary). It stabilizes misfolded transthyretin proteins, reducing the risk of heart-related death and hospitalization.
Rapiblyk-Landiolol
Rapiblyk is an IV beta-blocker used in hospitals to quickly control heart rate during acute supraventricular tachycardia (like atrial fibrillation or flutter). Its ultra-rapid action slows the heart without significantly lowering blood pressure.
Crenessity-Crinecerfont
Crenessity is used to treat classic congenital adrenal hyperplasia. It is administered together with glucocorticoids to control androgen levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia.
Iomervu-Iomeprol
Iomervu is an injectable contrast agent for CT scans and angiography in adults and children. It enhances artery and organ imaging by providing clear, safe visualization of vascular structures.
Hernexeos-Zongertinib
Hernexeos is an oral tyrosine kinase inhibitor used to treat adult patients with unresectable or metastatic non-squamous non-small cell lung cancer (NSCLC) whose tumors harbor HER2 (ERBB2) tyrosine kinase domain (TKD) activating mutations. Treatment is indicated following prior systemic therapy, and eligibility requires confirmation of the HER2 mutation via an FDA-approved test.
Brinsupri-Brensocatib
Brinsupri is an oral, once-daily dipeptidyl peptidase-1 (DPP1) inhibitor for the treatment of non-cystic fibrosis bronchiectasis (NCFB) in adults and adolescents aged 12 years and older. It represents the first FDA-approved targeted therapy for this chronic, progressive lung disease, directly addressing neutrophil-driven inflammation rather than just symptom management.
